IMPORTANT SAFETY INFORMATION
XELPROS is contraindicated in patients with a known hypersensitivity to latanoprost, or any other
ingredients in this product.
WARNINGS AND PRECAUTIONS
Pigmentation: XELPROS may cause changes to pigmented tissues. The most frequently reported
changes are increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is
expected to increase as long as XELPROS is administered. After discontinuation of XELPROS, iris pigmentation
is likely to be permanent. Patients who receive treatment should be informed of the possibility of increased
pigmentation. The long-term effects of increased pigmentation are not known.
Eyelash Changes: XELPROS may gradually change eyelashes and vellus hair in the treated
eye, including increased length, thickness, pigmentation, and number of lashes. The changes are usually
reversible upon discontinuation of treatment.
Intraocular Inflammation: XELPROS should be used with caution in patients with a history
of intraocular inflammation (iritis/uveitis) and should generally not be used in patients with active
Macular Edema: XELPROS should be used with caution in aphakic patients, in pseudophakic
patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
Herpetic Keratitis: XELPROS should be used with caution in patients with a history of
herpetic keratitis. XELPROS should be avoided in cases of active herpes simplex keratitis because
inflammation may be exacerbated.
Bacterial Keratitis: There have been reports of bacterial keratitis associated with the
use of multiple-dose containers of topical ophthalmic products.
Use with Contact Lenses: Contact lenses should be removed prior to administration of
XELPROS and may be reinserted 15 minutes following administration.
The most common ocular adverse reactions in clinical trials (incidence ≥5%) for XELPROS were eye
pain/stinging, ocular hyperemia, conjunctival hyperemia, eye discharge, growth of eyelashes, and eyelash
Precipitation may occur if drugs containing thimerosal are used concomitantly with XELPROS. If such drugs
are used, they should be administered at least 5 minutes apart.
Please see the Full Prescribing